<p>MacroGenics（納斯達克股票代碼：MGNX - 獲取免費報告）於週一發佈了季度財報。這家生物製藥公司報告本季度每股收益為（$0.22），超出分析師一致預期的（$0.42）$0.20。該公司本季度的收入為 4123 萬美元，而分析師的預期為 2781 萬美元。MacroGenics 的淨利潤率為負的 59.46%，股本回報率為負的 98.30%。</p>
<h2>MacroGenics 股票上漲 22.8%</h2>
<p>週二，MacroGenics 的股票在交易時段上漲了$0.54，達到$2.90。該股票成交量為 1,011,313 股，而其平均成交量為 824,034 股。該公司的市值為 1.8333 億美元，市盈率為-2.39，貝塔值為 1.45。公司 50 日移動平均價格為$1.80，200 日移動平均價格為$1.68。MacroGenics 的年內最低價為$0.99，年內最高價為$2.88。</p>
<h2>華爾街分析師預測增長</h2>
<p>MGNX 已成為多份分析師報告的主題。Zacks Research 在 1 月 1 日的報告中將 MacroGenics 的股票評級從 “強力買入” 下調至 “持有”。Weiss Ratings 在 12 月 22 日的研究報告中重申了對 MacroGenics 股票的 “賣出（d-）” 評級。最後，花旗集團在 2 月 24 日的研究報告中重申了對 MacroGenics 股票的 “市場表現” 評級。一位股票研究分析師給予該股票 “強力買入” 評級，一位給予 “買入” 評級，五位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，平均目標價為$3.60。</p>
<p><strong>查看我們關於 MacroGenics 的最新研究報告</strong></p>
<h2>對 MacroGenics 的對沖基金看法</h2>
<p>一些大型投資者最近對該公司的持倉進行了調整。Bridgeway Capital Management LLC 在第二季度將其在 MacroGenics 的持股增加了 16.1%。Bridgeway Capital Management LLC 現在擁有 133,700 股生物製藥公司的股票，價值 162,000 美元，此前在上個季度購買了 18,500 股。Algert Global LLC 在第三季度購買了價值 148,000 美元的 MacroGenics 新股份。BNP Paribas Financial Markets 在第三季度將其在 MacroGenics 的持股增加了 87.9%。BNP Paribas Financial Markets 現在擁有 86,671 股生物製藥公司的股票，價值 146,000 美元，此前在上個季度購買了 40,539 股。LPL Financial LLC 在第四季度將其在 MacroGenics 的持股增加了 181.2%。LPL Financial LLC 現在擁有 65,125 股生物製藥公司的股票，價值 105,000 美元，此前在上個季度購買了 41,967 股。最後，Invesco Ltd.在第一季度將其在 MacroGenics 的持股增加了 90.0%。Invesco Ltd.現在擁有 68,377 股生物製藥公司的股票，價值 87,000 美元，此前在上個季度購買了 32,398 股。96.89% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 MacroGenics</h2>
<p>（獲取免費報告）</p>
<p>MacroGenics, Inc 是一家臨牀階段的生物製藥公司，專注於單克隆抗體基礎治療的發現和開發，旨在治療癌症和自身免疫疾病。該公司利用專有的 Fc 工程技術來增強免疫參與並延長其抗體的活性。自 2000 年成立以來，MacroGenics 已將多個產品候選者推進臨牀試驗，最著名的是 margetuximab，這是一種針對 HER2 的抗體，旨在改善 HER2 陽性乳腺癌患者的治療效果。</p>
<p>MacroGenics 研究平台的核心是其 ADAPTIR 和 Trident 雙特異性抗體技術。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 MacroGenics 更好</li>
<li>為什麼這種稀有資源配置引起了早期關注</li>
<li>黃金的下一個上漲即將到來</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>美國的 1776 再次發生</li>
<li>在 2026 年 5 月 15 日之前購買這隻黃金股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUdOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUdOWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 MacroGenics 嗎？</h2>
<p>在考慮 MacroGenics 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 MacroGenics 並不在名單上。</p>
<p>雖然 MacroGenics 目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>MacroGenics（納斯達克代碼：MGNX）報告季度每股收益為（$0.22），超出預期的（$0.42）$0.20。公司實現收入為 4123 萬美元，超過了 2781 萬美元的預測。儘管股本回報率為負的 98.30% 和淨利潤率為 59.46%，但股價上漲了 22.8%，達到$2.90。分析師的評級意見不一，普遍評級為 “持有”，平均目標價為$3.60。機構投資者持有 96.89% 的股份，反映出對這家生物製藥公司的強烈興趣</p>

<p>MacroGenics (NASDAQ:MGNX - Get Free Report) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.20, reports. The business had revenue of $41.23 million for the quarter, compared to analysts' expectations of $27.81 million. MacroGenics had a negative net margin of 59.46% and a negative return on equity of 98.30%.</p>
<div class="lb-trans"><p>MacroGenics（納斯達克股票代碼：MGNX - 獲取免費報告）於週一發佈了季度財報。這家生物製藥公司報告本季度每股收益為（$0.22），超出分析師一致預期的（$0.42）$0.20。該公司本季度的收入為 4123 萬美元，而分析師的預期為 2781 萬美元。MacroGenics 的淨利潤率為負的 59.46%，股本回報率為負的 98.30%。</p>
</div><h2>MacroGenics Stock Up 22.8%</h2>
<div class="lb-trans"><h2>MacroGenics 股票上漲 22.8%</h2>
</div><p>Shares of MacroGenics stock traded up $0.54 during trading hours on Tuesday, reaching $2.90. 1,011,313 shares of the stock traded hands, compared to its average volume of 824,034. The firm has a market capitalization of $183.33 million, a price-to-earnings ratio of -2.39 and a beta of 1.45. The company has a 50 day moving average price of $1.80 and a 200 day moving average price of $1.68. MacroGenics has a one year low of $0.99 and a one year high of $2.88.</p>
<div class="lb-trans"><p>週二，MacroGenics 的股票在交易時段上漲了$0.54，達到$2.90。該股票成交量為 1,011,313 股，而其平均成交量為 824,034 股。該公司的市值為 1.8333 億美元，市盈率為-2.39，貝塔值為 1.45。公司 50 日移動平均價格為$1.80，200 日移動平均價格為$1.68。MacroGenics 的年內最低價為$0.99，年內最高價為$2.88。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>MGNX has been the topic of several analyst reports. Zacks Research cut shares of MacroGenics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, January 1st. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of MacroGenics in a research note on Monday, December 22nd. Finally, Citigroup reiterated a &#34;market perform&#34; rating on shares of MacroGenics in a research report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and an average target price of $3.60.</p>
<div class="lb-trans"><p>MGNX 已成為多份分析師報告的主題。Zacks Research 在 1 月 1 日的報告中將 MacroGenics 的股票評級從 “強力買入” 下調至 “持有”。Weiss Ratings 在 12 月 22 日的研究報告中重申了對 MacroGenics 股票的 “賣出（d-）” 評級。最後，花旗集團在 2 月 24 日的研究報告中重申了對 MacroGenics 股票的 “市場表現” 評級。一位股票研究分析師給予該股票 “強力買入” 評級，一位給予 “買入” 評級，五位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “持有”，平均目標價為$3.60。</p>
</div><p><strong>View Our Latest Research Report on MacroGenics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 MacroGenics 的最新研究報告</strong></p>
</div><h2>Hedge Funds Weigh In On MacroGenics</h2>
<div class="lb-trans"><h2>對 MacroGenics 的對沖基金看法</h2>
</div><p>A number of large investors have recently made changes to their positions in the business. Bridgeway Capital Management LLC grew its holdings in MacroGenics by 16.1% in the second quarter. Bridgeway Capital Management LLC now owns 133,700 shares of the biopharmaceutical company's stock valued at $162,000 after purchasing an additional 18,500 shares during the last quarter. Algert Global LLC bought a new stake in MacroGenics in the third quarter valued at $148,000. BNP Paribas Financial Markets raised its holdings in MacroGenics by 87.9% during the third quarter. BNP Paribas Financial Markets now owns 86,671 shares of the biopharmaceutical company's stock worth $146,000 after purchasing an additional 40,539 shares in the last quarter. LPL Financial LLC increased its stake in MacroGenics by 181.2% in the 4th quarter. LPL Financial LLC now owns 65,125 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 41,967 shares in the last quarter. Finally, Invesco Ltd. grew its position in MacroGenics by 90.0% during the first quarter. Invesco Ltd. now owns 68,377 shares of the biopharmaceutical company's stock valued at $87,000 after purchasing an additional 32,398 shares in the last quarter. 96.89% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投資者最近對該公司的持倉進行了調整。Bridgeway Capital Management LLC 在第二季度將其在 MacroGenics 的持股增加了 16.1%。Bridgeway Capital Management LLC 現在擁有 133,700 股生物製藥公司的股票，價值 162,000 美元，此前在上個季度購買了 18,500 股。Algert Global LLC 在第三季度購買了價值 148,000 美元的 MacroGenics 新股份。BNP Paribas Financial Markets 在第三季度將其在 MacroGenics 的持股增加了 87.9%。BNP Paribas Financial Markets 現在擁有 86,671 股生物製藥公司的股票，價值 146,000 美元，此前在上個季度購買了 40,539 股。LPL Financial LLC 在第四季度將其在 MacroGenics 的持股增加了 181.2%。LPL Financial LLC 現在擁有 65,125 股生物製藥公司的股票，價值 105,000 美元，此前在上個季度購買了 41,967 股。最後，Invesco Ltd.在第一季度將其在 MacroGenics 的持股增加了 90.0%。Invesco Ltd.現在擁有 68,377 股生物製藥公司的股票，價值 87,000 美元，此前在上個季度購買了 32,398 股。96.89% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About MacroGenics</h2>
<div class="lb-trans"><h2>關於 MacroGenics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.</p>
<div class="lb-trans"><p>MacroGenics, Inc 是一家臨牀階段的生物製藥公司，專注於單克隆抗體基礎治療的發現和開發，旨在治療癌症和自身免疫疾病。該公司利用專有的 Fc 工程技術來增強免疫參與並延長其抗體的活性。自 2000 年成立以來，MacroGenics 已將多個產品候選者推進臨牀試驗，最著名的是 margetuximab，這是一種針對 HER2 的抗體，旨在改善 HER2 陽性乳腺癌患者的治療效果。</p>
</div><p>Central to MacroGenics' research platform are its ADAPTIR and Trident bispecific antibody technologies.</p>
<div class="lb-trans"><p>MacroGenics 研究平台的核心是其 ADAPTIR 和 Trident 雙特異性抗體技術。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than MacroGenics</li>
<li>Why this rare resource setup is catching early attention</li>
<li>Gold's Next Surge is Imminent</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>America’s 1776 happening again</li>
<li>Buy this Gold Stock Before May 15th, 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 MacroGenics 更好</li>
<li>為什麼這種稀有資源配置引起了早期關注</li>
<li>黃金的下一個上漲即將到來</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>美國的 1776 再次發生</li>
<li>在 2026 年 5 月 15 日之前購買這隻黃金股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUdOWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=MGNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MacroGenics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 MacroGenics 嗎？</h2>
</div><p>Before you consider MacroGenics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 MacroGenics 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 MacroGenics 並不在名單上。</p>
</div><p>While MacroGenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MacroGenics 目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Market Beat

醫療業 ETF - Vanguard

生物科技 ETF - VanEck Vectors

2 倍做多納斯達克生物技術 ETF - ProShares

醫藥突破 ETF - ALPS

標普全球醫療股指數 ETF - iShares

標普生物技術 3 倍做空 - Direxion

美國制藥 ETF - iShares

標普生物技術 ETF - SPDR

基因改革 ETF - ARK

Macrogenics

Invesco Nasdaq Biotechnology ETF

醫療業 ETF - SPDR

MacroGenics（納斯達克代碼：MGNX）公佈季度財報，每股收益比預期高出 0.20 美元